查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578246

全球阿哌沙班市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Apixaban Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格

全球阿哌沙班市场需求预计将从2023年的173.6亿美元达到近337.1亿美元的市场规模，2024-2032年研究期间复合年增长率为7.65%。

阿哌沙班是一种抗凝血药物，用于治疗和预防非瓣膜性心房颤动患者的血栓和中风。阿哌沙班是一种血液稀释剂，旨在防止髋关节或膝关节置换手术后形成血栓，可能导致肺部血栓（肺栓塞）。它用来代替华法林，因为它不需要血液检查或饮食限制。阿哌沙班属于 Xa 因子抑制剂类药物。它的作用是阻止一种有助于血栓形成的天然物质。阿哌沙班以 Eliquis 名称上市。它以片剂形式口服。最常见的副作用是出血和噁心。不建议在怀孕或哺乳期间服用阿哌沙班。对于患有轻度肾臟问题的人来说，使用似乎相对安全。 Eliquis 与华法林相比，与较少的药物产生交互作用。

市场动态

阿哌沙班治疗适应症的不断增加，心房颤动、静脉血栓栓塞和中风盛行率的增加，大大促进了市场的成长。此外，老年人口的增加和肥胖症盛行率的增加正在补充市场的发展。此外，全球医疗保健支出的激增以及政府和私人组织对医疗保健研究和开发的大量投资的增加是推动阿哌沙班市场的其他关键因素。此外，新兴经济体的潜力不断增长，以及医疗保健领域的技术进步和现代化程度不断提高，将扩大阿哌沙班的市场。然而，阿哌沙班的副作用，例如服用太早会增加血栓事件和出血的风险，可能会限制其使用，从而阻碍市场成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对阿哌沙班全球市场的每个细分市场进行了包容性评估。阿哌沙班产业的成长和趋势为本研究提供了整体方法。

市场区隔

阿哌沙班市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

依剂型分类

  • 胶囊
  • 药片

按最终用户

  • 医院
  • 诊所
  • 零售药局
  • 网路药局
  • 其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲阿哌沙班市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。阿哌沙班市场的主要参与者包括罗氏公司、Hikma Pharmaceuticals PLC、卫材有限公司、赛诺菲公司、一诺製药有限公司、Mylan NV、百时美施贵宝公司、雅培实验室、河北常山生化製药有限公司、南京健友生化製药有限公司、Aspen Holdings、Fresenius Kabi AG、辉瑞公司等。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：APIXABAN - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按剂型分類的市场吸引力分析
    • 最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球 APIXABAN 市场分析：按剂型

  • 按剂型概述
  • 历史和预测数据
  • 按剂型分析
  • 胶囊
  • 药片

第 6 章：全球 APIXABAN 市场分析：依最终使用者分类

  • 最终用户概述
  • 历史和预测数据
  • 最终用户分析
  • 医院
  • 诊所
  • 零售药局
  • 网路药局
  • 其他的

第 7 章：全球 APIXABAN 市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 8 章：APIXABAN 公司的竞争格局

  • 阿哌沙班市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 9 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • F. Hoffmann-La Roche Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Hikma Pharmaceuticals PLC
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eisai Co. Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Sanofi SA
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Yino Pharma Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Mylan NV
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol Myers Squibb Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Abbott Laboratories
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Aspen Holdings
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Fresenius Kabi AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • 其他的
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资讯和最新发展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11216577

The global demand for Apixaban Market is presumed to reach the market size of nearly USD 33.71 Billion by 2032 from USD 17.36 Billion in 2023 with a CAGR of 7.65% under the study period 2024-2032.

Apixaban is an anticoagulant drug used to treat and prevent blood clots and strokes in people with nonvalvular atrial fibrillation. Apixaban is a blood thinner that is intended to prevent blood clots from forming following hip or knee replacement surgery, which can lead to lungs blood clots (pulmonary embolism). It's used instead of warfarin because it doesn't require blood tests or dietary restrictions. Apixaban belongs to the factor Xa inhibitors class of drugs. It works by stopping a natural substance that assist in the formation of blood clots. Apixaban is marketed under the name Eliquis. It is taken orally in the form of tablets. The most common side effects are bleeding and nausea. It is not recommended to take apixaban while pregnant or breastfeeding. In people with mild renal issues, it appears to be relatively safe to use. Eliquis interacts with fewer medications than warfarin.

MARKET DYNAMICS

Rising therapeutic indications for apixaban, an increase in the prevalence of atrial fibrillation, venous thromboembolism, and stroke are substantially contributing to the market growth. Furthermore, an increase in the geriatric population, an increase in the prevalence of obesity are supplementing market development. Additionally, a rising surge in healthcare expenditures worldwide and increasing government and private organizations investing significantly in healthcare research and development are other key factors driving the apixaban market. Moreover, rising potential in emerging economies, and increasing technological advancements and modernization in the healthcare sector, will expand the market for apixaban. However, apixaban's side effects, such as an increased risk of thrombotic events and bleeding if taken too soon, are likely to limit its use, thereby hampering the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Apixaban. The growth and trends of Apixaban industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Apixaban market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage Form

  • Capsule
  • Tablet

By End-User

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Apixaban market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Apixaban market include F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Eisai Co. Ltd, Sanofi S.A., Yino Pharma Limited, Mylan N.V., Bristol Myers Squibb Company, Abbott Laboratories, Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd., Aspen Holdings, Fresenius Kabi AG, Pfizer Inc., Others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. APIXABAN - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Dosage Form
    • 3.7.2 Market Attractiveness Analysis By End-User
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL APIXABAN MARKET ANALYSIS BY DOSAGE FORM

  • 5.1. Overview By Dosage Form
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Dosage Form
  • 5.4. Capsule Historic and Forecast Sales By Regions
  • 5.5. Tablet Historic and Forecast Sales By Regions

6. GLOBAL APIXABAN MARKET ANALYSIS BY END-USER

  • 6.1. Overview By End-User
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By End-User
  • 6.4. Hospitals Historic and Forecast Sales By Regions
  • 6.5. Clinics Historic and Forecast Sales By Regions
  • 6.6. Retail Pharmacies Historic and Forecast Sales By Regions
  • 6.7. Online Pharmacies Historic and Forecast Sales By Regions
  • 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL APIXABAN MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE APIXABAN COMPANIES

  • 8.1. Apixaban Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF APIXABAN INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. F. Hoffmann-La Roche Ltd
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Hikma Pharmaceuticals PLC
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Eisai Co. Ltd
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Sanofi S.A.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Yino Pharma Limited
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Mylan N.V.
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Bristol Myers Squibb Company
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Abbott Laboratories
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Hebei Changshan Biochemical Pharmaceutical Co. Ltd
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. Aspen Holdings
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Fresenius Kabi AG
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments
  • 9.15. Pfizer Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Company Revenue
    • 9.15.3 Products
    • 9.15.4 Recent Developments
  • 9.16. Others
    • 9.16.1 Company Overview
    • 9.16.2 Company Revenue
    • 9.16.3 Products
    • 9.16.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Dosage Form (USD MN)
  • Capsule Market Sales By Geography (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Analysis By End-User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Apixaban Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Apixaban Report
  • Market Research Process
  • Market Research Methodology
  • Global Apixaban Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Dosage Form
  • Market Attractiveness Analysis By End-User
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Dosage Form (USD MN)
  • Capsule Market Sales By Geography (USD MN)
  • Tablet Market Sales By Geography (USD MN)
  • Global Market Analysis By End-User (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Retail Pharmacies Market Sales By Geography (USD MN)
  • Online Pharmacies Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.